The European Commission has approved Sanofi and Regeneron’s Praluent for reducing cardiovascular risk in adults with established atherosclerotic CV disease (ASCVD), giving the drug another ...

Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...

The Regeneron alliance also yielded Sanofi’s under-performing cholesterol drug Praluent (alirocumab), which has failed to make much progress in a largely generic market and could soon be facing ...

Regeneron records net product sales of Praluent in the United States and Sanofi does the same outside the country. SNY pays REGN a royalty on such sales. Regeneron records global net product sales ...

We and Sanofi equally share profits from sales within ... Across the rest of Regeneron's product portfolio, cholesterol meds Evkeeza and Praluent earned $126m and $242m of revenues respectively ...

Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators ...

Regeneron Pharmaceuticals, Inc. REGN reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks Consensus Estimate of $11.62. The company recorded an EPS of $11.86 in the ...

Praluent (Alirocumab): Sanofi Praluent (Alirocumab) is a PCSK9 inhibitor used to lower LDL cholesterol in patients with Atherosclerotic Cardiovascular Disease (ASCVD) who are inadequately controlled ...

Sanofi has removed (PDF) a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers ...

Updated guidance on preventing atherosclerotic cardiovascular disease in people with dyslipidemia includes changes reflecting ...

Without medicine, it was 310 mg/dL. When I was put on Praluent by injection once a month, my cholesterol went down to 182 mg/dL. Although I don’t have many side effects, it is very expensive.